Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–10. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Roberts SE, Morrison-Rees S, Samuel DG, Thorne K, Akbari A, Williams JG. Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment Pharmacol Ther. 2016;43:334–345. doi:10.1111/apt.13474.
   PubMed Web of Science ®Google Scholar
• Abrams JA, Gonsalves L, Neugut AI. Diverging trends in the incidence of reflux-related and Helicobacter pylori-related gastric cardia cancer. J Clin Gastroenterol. 2013;47:322–327. doi:10.1097/MCG.0b013e318260177a.
   PubMed Web of Science ®Google Scholar
• Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–248. doi:10.3322/caac.21185.
   PubMed Web of Science ®Google Scholar
• Parmiani G. Tumor-infiltrating T cells - Friend or foe of neoplastic cells? New Engl J Med. 2005;353:2640–2641. doi:10.1056/NEJMp058236.
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene. 2010;29:1093–1102. doi:10.1038/onc.2009.416.
   PubMed Web of Science ®Google Scholar
• Kong JC, Guerra GR, Pham T, Mitchell C, Lynch AC, Warrier SK, Ramsay RG, Heriot AG. Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: A systematic review and meta-analysis. Dis Colon Rectum. 2019;62:498–508. doi:10.1097/DCR.0000000000001332.
   PubMed Web of Science ®Google Scholar
• Vihervuori H, Autere TA, Repo H, Kurki S, Kallio L, Lintunen MM, Talvinen K, Kronqvist P. Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. J Cancer Res Clin Oncol. 2019;145:3105–3114. doi:10.1007/s00432-019-03036-5.
   PubMed Web of Science ®Google Scholar
• Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012:14. doi:10.1186/bcr3148.
   Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol. 2014;232:199–209. doi:10.1002/path.4287.
   PubMed Web of Science ®Google Scholar
• Schumacher K, Haensch W, Röefzaad C, Schlag PM. Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61:3932–3936.
   PubMed Web of Science ®Google Scholar
• Zheng X, Song X, Shao Y, Xu B, Chen L, Zhou Q, Hu W, Zhang D, Wu C, Tao M, et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017;8:57386–57398. doi:10.18632/oncotarget.18065.
   PubMedGoogle Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer- the stable evidence. Nat Rev Clin Oncol. 2010;7:153–162. doi:10.1038/nrclinonc.2009.237.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Ghidini M, Cabiddu M, Pezzica E, Corti D, Turati L, Costanzo A, Varricchio A, Ghidini S, Barni S, et al. Microsatellite instability and survival in stage II colorectal cancer: A systematic review and meta-analysis. Anticancer Res. 2019;39:6431–6441. doi:10.21873/anticanres.13857.
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–618. doi:10.1200/JCO.2005.01.086.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber, BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med. 2015;372:2509–2520. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Lee V, Murphy A, Le DT, Diaz LA. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21:1200–1211. doi:10.1634/theoncologist.2016-0046.
   PubMed Web of Science ®Google Scholar
• Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Annal Oncol. 2019;30:1096–1103. doi:10.1093/annonc/mdz134.
   PubMed Web of Science ®Google Scholar
• Fang WL, Chang SC, Lan YT, Huang KH, Chen JH, Lo SS,  Hsieh M-C, Li AF-Y, Wu CW, Chiou SH, et al. Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg. 2012;36:2131–2138. doi:10.1007/s00268-012-1652-7.
   PubMed Web of Science ®Google Scholar
• Polom K, Marano L, Marrelli D, De Luca R, Roviello G, Savelli V, Tan P, Roviello F, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;105:159–167. doi:10.1002/bjs.10663.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z,  Fassan M, Rugge M, Valeri N, Okines A, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3:1197–1203. doi:10.1001/jamaoncol.2016.6762.
   PubMed Web of Science ®Google Scholar
• Seliger B. Basis of PD1/PD-L1 Therapies. J Clin Med. 2019;8:2168. doi:10.3390/jcm8122168.
   PubMed Web of Science ®Google Scholar
• Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:1–11. doi:10.1038/ncomms14572.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–477. doi:10.1038/nri2326.
   PubMed Web of Science ®Google Scholar
• Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoints in cancer clinical trials. Chin J Cancer. 2014;33:434–444. doi:10.5732/cjc.014.10122.
   PubMed Web of Science ®Google Scholar
• La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35:963–976. doi:10.1002/phar.1643.
   PubMed Web of Science ®Google Scholar
• Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Bockmayr M, Dietel M, Denkert C, Braicu L, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2015;7:1486–1499. doi:10.18632/oncotarget.6429.
   Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381–3385. doi:10.1158/0008-5472.CAN-05-4303.
   PubMed Web of Science ®Google Scholar
• Böger C, Behrens HM, Mathiak M, Krüger S, Kalthoff H, Röcken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016;7:24269–24283. doi:10.18632/oncotarget.8169.
   PubMed Web of Science ®Google Scholar
• Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Horst D, Rau B, U Stein U, Treese C. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. Pathol Res Pract. 2019;215:152662. doi:10.1016/j.prp.2019.152662.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006;100:229–235. doi:10.1007/s10549-006-9242-8.
   PubMed Web of Science ®Google Scholar
• Chiaravalli AM, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R, Capella C. Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2006;448:344–353. doi:10.1007/s00428-005-0066-4.
   PubMed Web of Science ®Google Scholar
• Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006;55:1064–1071. doi:10.1007/s00262-005-0092-8.
   PubMed Web of Science ®Google Scholar
• Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES,  Shin SW, Kim YH, Kim JS, Park KH. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 2013;36:224–231. doi:10.1097/COC.0b013e3182467d90.
   PubMed Web of Science ®Google Scholar
• Pandya PH, Murray ME, Pollok KE, Renbarger JL. The immune system in cancer pathogenesis: potential therapeutic approaches. J Immunol Res. 2016:2016. doi:10.1155/2016/4273943.
   Web of Science ®Google Scholar
• Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2019:1–15. doi:10.1016/j.semcancer.2019.07.017.
   Web of Science ®Google Scholar
• Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Saraf S, Koshiji M, Csiki I, Bennouna J. Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. J Clin Oncol. 2016;34:4046. doi:10.1200/jco.2016.34.15_suppl.4046.
   Web of Science ®Google Scholar
• Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, Bennouna  J. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. 2018;36:61–67. doi:10.1200/JCO.2017.74.9846.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Bang Y-J, Fuchs CS, Wyrwicz L, Lee KW,  Kudaba I, Garrido M, Chung HC, Castro Salguero HR, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. J Clin Oncol. 2019;37:LBA4007–LBA4007. doi:10.1200/JCO.2019.37.18_suppl.LBA4007.
   Web of Science ®Google Scholar
• Kawazoe A, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai K, Hara H, Baba H, Tsuda M, Hosaka H, et al. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: cohort 1 data from the KEYNOTE-659 phase IIb study. Eur J Cancer. 2020;129:97–106. doi:10.1016/j.ejca.2020.02.002.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Hwang JJ, Shields AF, Salem ME, Marshall JL. Immuno‐oncology biomarkers for gastric and gastroesophageal junction adenocarcinoma: why PD‐L1 testing may not be enough. Oncologist. 2018;23:1171–1177. doi:10.1634/theoncologist.2018-0034.
   PubMed Web of Science ®Google Scholar
• Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J,  Zhong X, Li X, Qian H, Wang X. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS ONE. 2017;12:1–14. doi:10.1371/journal.pone.0182692.
   Web of Science ®Google Scholar
• Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2016;66:794–801. doi:10.1136/gutjnl-2015-310839.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T Zhao T, Wang Q, Jiang J. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Lancet Oncol. 2008;9:279–287. doi:10.1016/S1470-2045(08)70072-X.
   PubMedGoogle Scholar
• Khouja MH, Baekelandt M, Sarab A, Nesland JM, Holm R. Limitations of tissue microarrays compared with whole tissue sections in survival analysis. Oncol Lett. 2010;1:827–831. doi:10.3892/ol_00000145.
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C , Chung HC, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123–133. doi:10.1016/S0140-6736(18)31257-1.
   PubMed Web of Science ®Google Scholar